N-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-3H-benzimidazole-4-carboxamide
C18H17BrF3N5O — CID 122686699
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-3H-benzimidazole-4-carboxamide
N-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-3H-benzimidazole-4-carboxamide (PubChem CID 122686699) has the molecular formula C18H17BrF3N5O and a molecular weight of 456.27 g/mol. Its IUPAC name is N-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-3H-benzimidazole-4-carboxamide.
Molecular Properties
| Compound Name | N-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-3H-benzimidazole-4-carboxamide |
|---|---|
| PubChem CID | 122686699 |
| Molecular Formula | C18H17BrF3N5O |
| Molecular Weight | 456.27 g/mol |
| Exact Mass | 455.06 |
| IUPAC Name | N-(3-bromo-4-fluorophenyl)-2-[2-(dimethylamino)ethylamino]-6,7-difluoro-3H-benzimidazole-4-carboxamide |
| SMILES | CN(C)CCNc1nc2c(F)c(F)cc(C(=O)Nc3ccc(F)c(Br)c3)c2[nH]1 |
| InChI | InChI=1S/C18H17BrF3N5O/c1-27(2)6-5-23-18-25-15-10(8-13(21)14(22)16(15)26-18)17(28)24-9-3-4-12(20)11(19)7-9/h3-4,7-8H,5-6H2,1-2H3,(H,24,28)(H2,23,25,26) |
| InChIKey | WSKVVKBGIHRSLV-UHFFFAOYSA-N |
| XLogP | 3.97 |
| TPSA | 73.05 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 456.27 |
| LogP ≤ 5 | 3.97 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 122686699 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.